Approximately one-quarter of people over the age of 65 are estimated to suffer some form of cognitive impairment, underscoring the need for effective cognitive-enhancing agents. Insulin-regulated aminopeptidase (IRAP) is potentially an innovative target for the development of cognitive enhancers, as its peptide inhibitors exhibit memory-enhancing effects in both normal and memory-impaired rodents. Using a homology model of the catalytic domain of IRAP and virtual screening, we have identified a class of nonpeptide, small-molecule inhibitors of IRAP. Structure-based computational development of an initial "hit" resulted in the identification of two divergent families of compounds. Subsequent medicinal chemistry performed on the highest affinity compound produced inhibitors with nanomolar affinities (K i 20 -700 nM) for IRAP. In vivo efficacy of one of these inhibitors was demonstrated in rats with an acute dose (1 nmol in 1 l) administered into the lateral ventricles, improving performance in both spatial working and recognition memory paradigms. We have identified a family of specific IRAP inhibitors that is biologically active which will be useful both in understanding the physiological role of IRAP and potentially in the development of clinically useful cognitive enhancers. Notably, this study also provides unequivocal proof of principal that inhibition of IRAP results in memory enhancement. The development of insulin-regulated aminopeptidase (IRAP; EC 3.4.11.3) inhibitors as drug candidates provides an alternative therapeutic class based on a novel target. Peptide inhibitors of IRAP, when administered centrally into the lateral ventricles, facilitate spatial and aversion-related memories in normal rodents (2-5). More importantly, these inhibitors restore memory in animals with memory deficits induced by alcohol (6), ischemia (7), perforant pathway lesions (4), or chemical perturbations of the septo-hippocampal cholinergic pathway (8 -11). The mechanisms whereby IRAP inhibitors facilitate memory are not fully understood (12), but recent studies implicate the involvement of neuroendocrine mechanisms. Inhibition of IRAP may extend the half-life of neuropeptides that modify learning and memory processes (13). Peptide substrates of IRAP include arginine-vasopressin, oxytocin, metenkephalin, somatostatin, dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) , and lysbradykinin, all of which are known to modulate memory (14, 15).
ditions, including cerebral ischemia or brain trauma. Most drugs under clinical development for the treatment of cognitive decline target the cholinergic system: The majority of U.S. Food and Drug Administration (FDA) approved drugs are cholinesterase inhibitors, and all demonstrate limited efficacy (1) . The development of insulin-regulated aminopeptidase (IRAP; EC 3.4.11.3) inhibitors as drug candidates provides an alternative therapeutic class based on a novel target. Peptide inhibitors of IRAP, when administered centrally into the lateral ventricles, facilitate spatial and aversion-related memories in normal rodents (2) (3) (4) (5) . More importantly, these inhibitors restore memory in animals with memory deficits induced by alcohol (6) , ischemia (7), perforant pathway lesions (4), or chemical perturbations of the septo-hippocampal cholinergic pathway (8 -11) . The mechanisms whereby IRAP inhibitors facilitate memory are not fully understood (12) , but recent studies implicate the involvement of neuroendocrine mechanisms. Inhibition of IRAP may extend the half-life of neuropeptides that modify learning and memory processes (13) . Peptide substrates of IRAP include arginine-vasopressin, oxytocin, metenkephalin, somatostatin, dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) , and lysbradykinin, all of which are known to modulate memory (14, 15) .
IRAP was first identified in adipocytes, where it was found associated with the inducible glucose transporter GLUT4. The protein coexists with GLUT4 in specialized vesicles and accompanies it to the plasma membrane in response to insulin stimulation (16) . In these insulin-responsive tissues, IRAP is proposed to play a role in the intracellular retention of GLUT4 vesicles (17) . This protein was also cloned from a placental cDNA library as oxytocinase and is thought to be the principal enzyme involved in the regulation of circulating oxytocin levels during pregnancy (18) . Most recently, it was demonstrated to be the specific binding site for the memory-enhancing peptides angiotensin IV (Ang IV) and LVV-hemorphin 7 (LVV-H7) (19) .
In the brain, IRAP is found in high concentrations in regions involved in cognitive function, including the cerebral cortex, hippocampus, basal forebrain, and amygdala (20) , where it is coexpressed with the glucose transporter GLUT4 in neurons. It was recently demonstrated that IRAP inhibitors increase activity-evoked glucose uptake into the pyramidal neurons of the hippocampus (21) . Glucose is a potent modulator of learning and memory in both humans and rodents (22) (23) (24) , with increases in glucose demand in the hippocampus occurring during memory processing (25) .
To date, the only published IRAP inhibitors are the peptides Ang IV and LVV-H7 (19) and their modified forms (26 -28) . Although these peptides are highaffinity, competitive inhibitors of IRAP (14, 15) , they display promiscuity at higher concentrations, binding to other proteins including aminopeptidase N (29, 30) . This, together with the rapid onset of some of the physiological responses of these peptides, has led some investigators to propose that IRAP is not the protein involved in mediating the central effects of Ang IV and LVV-H7 (31) . In addition to problems with selectivity, the peptide inhibitors have limited potential for development into clinically useful cognitive enhancers because of their other biochemical properties: susceptibility to degradation and lack of blood brain barrier permeability. In view of this, we have utilized a high-throughput computational docking approach (32, 33) to successfully identify new drug-like, nonpeptide inhibitors of IRAP.
MATERIALS AND METHODS

Generation of the homology model
The protease region of IRAP (residues L140 to S533) was modeled on the structure of the equivalent domain of another M1 aminopeptidase, leukotriene A4 hydrolase (LTA4H), (residues S8 to L389; PBD code 1HS6) (34) . While the overall identity between the sequences is low, the region immediately surrounding the active site residues, including the HEXXH and GXMEN motifs, is relatively well conserved, with 41% sequence identity. A sequence alignment of the catalytic domains of several members of the M1 aminopeptidase family, including IRAP and LTA4H, was used to guide model building. The model was built using COMPOSER in Sybyl6.8 (Tripos Inc., St. Louis, MO, USA) and minimized in Sybyl6.8 under the Tripos Force Field, with the final structure having more than 95% of residues in the allowed region of a Ramachandran plot. A zinc ion was manually added to the active site motif after comparison with the zinc-bound LTA4H structure indicated the conformation of residues in the zinc-binding motif was identical in the two proteins. The quality of the model was confirmed with Verify3D (35) (data not shown). Model structures were examined using Sybyl6.8.
In silico screening
Virtual compound libraries were assembled from online databases of a number of commercial suppliers. Prior to screening, the libraries were refined to select only "drug-like" compounds using FILTER (OpenEye, Santa Fe, NM, USA) giving ϳ1.5 million structures, which were then converted to three-dimensional (3D) structures using Omega (OpenEye). Virtual screening was carried out with FRED (OpenEye) using the ShapeGauss scoring function. The 58 compounds with the highest docking scores were purchased and tested in an in vitro IRAP enzymatic assay. A 3D similarity search using ROCS (OpenEye) was conducted initially on HFI-14 (compound with the highest affinity for IRAP in the first round of screening) and later on HFI-142. Compounds with high shape complementarity (Tanimoto coefficient Ͼ0.85) were selected for in vitro assays. A 2D similarity search was also performed using Unity (Tripos, St. Louis, MO, USA). Approximately 200 compounds with high shape or 2D complementarity (Tanimoto coefficient Ͼ0.85) were selected for in vitro assays.
Synthesis of compounds
The 2-amino-4-aryl-4H-chromene-3-carboxylic acid esters, including HFI-142 and HFI-435, were prepared from the appropriate aromatic aldehyde and phenol using general reaction conditions described elsewhere (36) .
Enzyme assays
IRAP
The enzymatic activity of IRAP (specific activity 10.6 U/mg) was determined by the hydrolysis of the synthetic substrate l-leucine 7-amido-4-methyl coumarin hydrochloride (Leu-MCA) (Sigma-Aldrich, St. Louis, MO, USA), monitored by the release of a fluorogenic product, MCA, at excitation and emission wavelengths of 380 and 440 nm, respectively, as described elsewhere (15) . Initial screenings for inhibitors utilized membrane preparations from HEKT cells transfected with pCI-IRAP (a gift from Masafumi Tsujimoto, RIKEN, Saitama, Japan) (15) , with subsequent analyses utilizing purified recombinant extracellular domain of IRAP obtained from insect cells (unpublished results).
LTA4H
Recombinant human LTA4H (Cayman Chemical, Ann Arbor, MI, USA) (specific activity 166 U/mg) was incubated at room temperature with 100 M alanine-␤-naphthylamide as substrate in 50 mM Tris-HCl buffer, pH 8.0, containing 100 mM KCl with or without increasing concentrations of an inhibitor. The fluorescence was measured at 320 nm excitation and 405 nm emission.
Aminopeptidase N
Aminopeptidase N (specific activity 40 U/mg) (Sigma Aldrich) was incubated with 250 M of substrate alanine-␤-naphthylamide (Sigma Aldrich) in Tris buffered saline (50 mM Tris-HCl, 150 mM NaCl pH 7.5) at 25°C. IRAP inhibitors (1-10 M) were added after 1 min and fluorescence was monitored at 320 nm excitation and 405 nm emission.
Endoplasmic reticulum-associated aminopeptidases 1 and 2 (ERAP1 and ERAP2)
The enzymatic activities of purified recombinant soluble ERAP1 and ERAP2 (specific activities 2.1 and 18.0 U/mg, respectively; unpublished results) were determined by the hydrolysis of the synthetic substrates, Leu-MCA and Arg-MCA, respectively (Sigma-Aldrich), using the same methodology as used with recombinant IRAP. Briefly, 1-10 g purified protein was incubated with the substrate (12.5 to 500 M) and inhibitors (10 nM to 1 mM) in 25 mM Tris, pH 7.4, with 150 mM NaCl. Activity was measured at excitation 380 nm and emission 440 nm.
Angiotensin converting enzyme (ACE)
ACE (specific activity 10 U/mg) (Sigma Aldrich) was incubated with 5 mM hippuryl-histidyl leucine (HHL) in 100 mM potassium buffer (pH 8.3) that contained 300 mM NaCl and 100 M ZnSO 4 for 30 min at 37°C. The enzymatic reaction was stopped by the addition of 0.28N NaOH, o-phthaldialdehyde (20 mg/ ml) in methanol was added, and the fluorescent reaction stopped by the addition of 200 l of 3N HCl. The product, l-HL, was measured fluorometrically at 360 nm excitation and 500 nm emission.
Determination of blood-brain barrier permeability
Compounds (5 mg/kg) dissolved in 1% (v/v) dimethyl sulfoxide (DMSO) were administered to male Swiss outbred mice intravenously. At various time points (5, 30, 60, and 240 min), the mice were anesthetized, and blood was obtained by cardiac puncture. Following cervical dislocation, the brain was removed, and both brain and plasma concentrations of compound were determined using liquid chromatography-mass spectrometry techniques. The amount of compound associated with the brain vasculature was subtracted (this was determined with a known brain vascular volume obtained following administration of the nonabsorbable marker 14 C-inulin) and the brain/plasma ratio was determined at each time point.
Surgical preparation of rats and drug treatment
All experiments were performed according to the National Health and Medical Research Council of Australia "Code of practice for the care and use of animals for scientific purposes." Male Sprague Dawley rats (250 -270 g) were housed individually and given water and standard rat chow ad libitum. The rats were anesthetized with 5% (v/v) isofluorane and stereotaxically implanted with a chronic indwelling cannula (Plastics One, Roanoke, VA, USA) into the cerebral lateral ventricle using the following flat skull coordinates: 0.8 mm posterior to bregma, 1.5 mm lateral to midline, and 3.5 mm ventral to the dura (37) . The cannula was then secured to the skull with stainless steel screws and dental cement. Seven days following surgery, correct cannula placement was verified by the dipsogenic response to angiotensin II (0.1 nmol in 2 l). For all behavioral tests, the animals were habituated for at least 2 h in the testing room, injected with 0.1 or 1 nmol HFI-419 in 2 l of 10% (v/v) DMSO or vehicle and then returned to their home cage for 5 min prior to testing.
Novel object recognition task
Prior to the acquisition trial, the rats were habituated for 5 min in the testing box (made from gray Perspex of dimensions 60ϫ60ϫ50 cm) in diffuse dim light and then returned to their home cage (38) . The rats were placed in the testing box facing away from 2 identical objects that had been secured to the floor in adjacent corners of the box. The rats were allowed 5 min to explore the objects, with exploration defined as the nose being less than 2 cm from the object when facing the object. On day 2 of testing, after an intertrial interval of 20 h, one of the objects was replaced by a novel object made from the same material but of a different shape, and the rats were given 2 min in the box. The recognition index was determined as the time spent exploring the novel object minus the time spent on the familiar object, divided by the time spent on both objects.
Spontaneous alternation plus maze
The plus maze was made of black plastic and composed of 4 arms, with each arm measuring 75 ϫ 10 ϫ 20 cm and visual cues placed 1 m away from the maze. Spontaneous alternation testing was conducted by placing the rat in the center of the maze and allowing 20 min of unimpeded exploration (39) . The number and sequence of arm entries were recorded for calculation of a percentage alternation score. An alternation consisted of 4 different arm choices over 5 consecutive arm entries. An alternation score was derived by dividing the number of observed alternations in overlapping quintuplets by the number of possible alternations.
Elevated plus maze
The maze consisted of 2 open arms (70ϫ10 cm) with a 5-cm high surrounding wall and 2 enclosed arms (70ϫ10 cm) with a 27-cm high surrounding wall. The floors were black laminate, the open arm walls were clear Perspex, and the closed arm walls black Perspex. The maze was elevated 85 cm above the ground. Rats were placed in the central platform facing one of the closed arms, and behavior was monitored for 10 min using Ethovision software (Noldus Information Technology, Wageningen, The Netherlands). The percentage of time spent in the open arms compared to the closed arms was a measure of the anxiety of the animals. The activity of each rat was video-recorded and scored automatically by the Ethovision software.
Locomotor cell activity
Locomotor activity of rats was monitored in cages measuring 40 ϫ 40 ϫ 40 cm (Coulbourn Instruments, Whitehall, PA, USA) equipped with infrared photobeams for 30 min. Activity was measured when pairs of photobeams spaced 2.54 cm apart, providing a 1.27-cm spatial resolution, were crossed. Data were collected and analyzed using TruScan Photo Beam Activity system (Coulbourn Instruments).
Hippocampal glucose uptake assay
Male Sprague-Dawley rats (250 -270 g) were anesthetized with Isofluorane and killed by decapitation. The brains were rapidly removed and placed into ice-cold, carbogen-bubbled, artificial cerebrospinal fluid (aCSF: 124 mM NaCl, 2.5 mM KCl, 2 mM CaClB 2B , 2 mM MgSOB 4B , 26 mM NaHCOB 3B , 1.25 mM NaHB 2B POB 4B , pH 7.4) supplemented with 10 mM d-glucose 
Statistical analysis
Statistical analyses were performed with GraphPad Prism (GraphPad Software Inc, San Diego, CA, USA) or SigmaStat (Systat Software, Chicago, IL, USA) software. Data are expressed as means Ϯ se and were analyzed with Student's t test (glucose uptake) or 1-or 2-way analysis of variance with Dunnett's post hoc analysis, where appropriate. A value of P Ͻ 0.05 was considered significant.
RESULTS
Molecular model of IRAP
In the absence of an experimentally determined structure of IRAP, a molecular model of the catalytic domain of IRAP was built based on the crystal structure of the related enzyme, LTA4H, bound to the metalloprotease inhibitor, bestatin ( Fig. 1) (34) . Analysis of models of the catalytic cleft of IRAP and LTA4H revealed an important difference, conferred by the amino acid residues L463 and A407 in IRAP, when compared to the corresponding amino acids F314 and Y267 in LTA4H (Fig. 1, insert) . The smaller amino acid side-chains of IRAP alter the shape of its catalytic cleft when compared to LTA4H, and we predicted that the difference in these residues would allow the in silico identification of potential ligands that are selective with respect to the structural template LTA4H, used for building the IRAP model, LTA4H.
Virtual screening
An in-house database of 1.5 million compounds was screened against the homology model of IRAP, and 58 compounds with the highest docking scores were purchased and tested in the IRAP aminopeptidase assay. A hit rate of ϳ10% was achieved, with 6 structurally distinct compounds inhibiting the activity of IRAP with K i values of Յ100 M. HFI-14 ( Fig. 2A) was selected for further development based on its relatively high affinity for IRAP and predicted drug-like properties. The binding of HFI-14 to the catalytic site of IRAP was proven by competitive enzyme kinetics and its specificity for IRAP was confirmed by insignificant inhibitory effects on a range of enzymes including the related aminopeptidases, LTA4H and aminopeptidase N.
A sequential analog identification strategy was then employed, based on both shape and structural similarity to HFI-14, and a further 200 compounds were selected and assayed for IRAP inhibitory activity. In the first approach, we searched for compounds in our chemical database that had similar 3D shapes to HFI-14, but not necessarily the same core chemical structure. In the second approach, we searched for compounds with a similar core chemical structure. The outcome of secondary and subsequent screenings was the identification of structural homologs of HFI-14 with improved inhibitory activity. The most active compound, HFI-142, exhibited a K i of 2 M (Fig. 2B) . Moreover, this screening approach identified a second family of structurally distinct inhibitors, albeit with lower activity (data not shown). Further development of the second family of IRAP inhibitors was not pursued at this time. The selectivity of the HFI-142 series for IRAP was tested experimentally and these compounds were found to exhibit limited inhibition of a range of related aminopeptidases and no inhibition of unrelated enzymes at concentrations of up to 100 M (results not shown).
Medicinal chemistry modification
To facilitate a hit-to-lead transition, the potency of the inhibitors needed to be increased at least 1 order of magnitude relative to the original HFI-14 compound. New derivatives with conservative modifications of the functional groups in HFI-142 [i.e., the 2-amino, 7-hydroxy, ester, and 4-(3-pyridyl) groups] were synthesized (Fig.  2C ). Thirty derivatives were purified and tested, with 12 structural analogs of HFI-142 displaying IRAP inhibitory activity.
Biochemical characterization of HFI-142 analogues
Three compounds, HFI-419 (ethyl 2-acetylamino-7-hydroxy-4-pyridin-3-yl-4H-chromene-3-carboxylate), made by acetylation of the 2-amino group of HFI-142; the quinoline analog HFI-435; and the hybrid molecule HFI-437 (ethyl 2-acetylamino-7-hydroxy-4-quinolin-3-yl-4H-chromene-3-carboxylate) exhibited K i values of Ͻ1 M (Fig. 2D-F) . The compound with the highest activity, HFI-437, exhibited a K i value of 20 nM, 250-fold higher than the original hit compound, HFI-14. The specificity of the HFI-142 analogs for IRAP was confirmed experimentally: The compounds exhibited much lower affinities (Ͼ1000-fold lower) for the structurally related enzymes, endoplasmic reticulum- associated aminopeptidase 1 and 2, aminopeptidase N, and, more important, LTA4H ( Table 1) . Unlike angiotensin IV, these compounds (at 100 M) were completely inactive in competing for angiotensin II binding to the AT 1 receptor (results not shown).
The physicochemical characteristics of HFI-142, HFI-419, HFI-435, and HFI-437 were evaluated by both in silico and experimental techniques. Solubility was assessed at pH 2.0 and 6.5 by turbidimetric assay. Under acidic conditions, all compounds display good solubility (Ͼ100 g/ml). At pH 6.5, HFI-142 and HFI-419 displayed moderate and similar solubility values, 25-50 and 50 -100 g/ml, respectively. Solubility values for HFI-435 and HFI-437 were significantly lower, at 3-6 and 6 -12 g/ml, respectively. The brain uptake of the 4 compounds in this series was low. Five minutes after an i.v. dose of 5 mg/kg, the mean brain-to-plasma (B:P) ratios were 0. 24 
Effects of HFI-419 in the central nervous system
To evaluate the central effects of these IRAP inhibitors, HFI-419 was selected on the basis of its relatively high affinity for IRAP and its solubility profile. Initially, the effect of HFI-419 was tested in vitro in a hippocampal slice assay to investigate whether the drug modulated glucose uptake. Consistent with the effect of peptide inhibitors of IRAP, HFI-419 at a concentration of 100 nM significantly increased dibutyryl cAMP-evoked glucose uptake in rat hippocampal slices (tϭ2.81, PϽ0.05) (Fig. 3) .
The effects of centrally administered HFI-419 on 2 distinct memory tasks were then investigated in rats. In the novel object recognition task, there was a significant treatment effect (F (2, 27) ϭ8.02, PϽ0.05) with rats treated with 0.1 or 1 nmol HFI-419 5 min prior to the acquisition trial spending significantly more time investigating the novel object than the familiar object following an intertrial interval of 20 h (PϽ0.05 and PϽ0.01, respectively). At this intertrial interval, control vehicle-treated rats did not discriminate between the familiar and the novel object, with recognition indices that did not differ significantly from chance performance (Fig. 4A) .
In the spontaneous alternation plus maze task, a significant treatment effect was detected in the alternation score (F (2, 21) ϭ6.18, PϽ0.01), with rats that received the dose of 0.1 nmol HFI-419 5 min prior to testing obtaining significantly higher alternation scores compared to control vehicle-treated rats (PϽ0.01), demonstrating enhanced spatial working memory (Fig. 4B) . In contrast, in the measurement of the number of arm entries, no significant treatment effect was detected (F (2, 21) ϭ0.90, PϾ0.05), indicating that the drug treatment did not alter the rate or speed of movement in the maze.
Since performance of the rats in the memory paradigms is dependent on their motor ability and state of mind, the effect of the HFI-419 on locomotor activity and anxiety levels was also tested in rats after central adminis- Determination of the inhibitory activity of the HFI-142 analogs for other enzymes. Results are expressed as percentage inhibition of the catalytic activity of the enzyme at the given concentration; n ϭ 3-4. ND, not determined.
tration. Rats treated with the doses of HFI-419 that elicited the memory effects displayed the same level of activity as the vehicle-treated controls, as determined by crossing of infrared beams in a locomotor cell over a period of 30 min (F (2, 21) ϭ0.80, PϾ0.05) (Fig. 4C) . The same doses of HFI-419 did not significantly alter the time spent in the open arms in the elevated plus maze (F (2, 22) ϭ0.60, PϾ0.05), which is a measure of anxiety (Fig. 4D) . Therefore, IRAP inhibition by HFI-419 selectively affects central mechanisms involved in memory processing, resulting in improved performance in memory tasks without impacting on locomotor activity or anxiety, factors that can influence the outcome of the memory tasks.
DISCUSSION
Effects of peptide inhibitors of IRAP in the central nervous system
The peptides Ang IV (VYIHPF) and LVV-H7 (LVVYP-WTQRF) exhibit very similar effects in the central nervous system, potentiating potassium-evoked acetylcholine release (40) and glucose uptake (21) from hippocampal slices, accelerating spatial learning in rats after a single acute dose (5) and ameliorating memory deficits induced by the muscarinic receptor antagonist, scopolamine (8, 9, 11) . In support of a role for Ang IV in memory processing, the hexapeptide was found to enhance long-term potentiation in the hippocampus in vitro (41) and in vivo (42) .
Both peptides bind with high affinity to IRAP (19) and are competitive inhibitors of the enzyme, but are not substrates (15) . In view of the biochemical and pharmacological properties of the 2 peptides, it is proposed that IRAP is involved in mediating their memory-enhancing effects. Consistent with this proposal, IRAP is abundantly expressed in neurons in the basal forebrain, amygdale, hippocampus, and entorhinal cortex (20, 43, 44) , brain regions that are integrally involved in memory processing. However, there is a level of promiscuity in these peptide IRAP inhibitors-at higher concentrations, Ang IV is capable of activating the angiotensin AT 1 receptor (45) and LVV-H7 the mu opioid receptor (46) . In addition, both peptides also interact with aminopeptidase N, albeit at significantly higher concentrations than to IRAP (29, 30) .
Provision of proof-of-concept that inhibition of IRAP results in facilitation of memory
The concept that IRAP is the central target of the memory enhancing peptides Ang IV and LVV-H7 has been controversial, with different groups proposing other targets for these peptides (31) . Therefore, the in silico identification of specific inhibitors of IRAP based on their binding to the catalytic domain of this enzyme taken through to the demonstration of memory enhancing effects in vivo provides substantial proof of this concept. The newly identified and characterized IRAP inhibitor, HFI-419, when administered into the cerebral ventricles of rats, dose-dependently improved visual recognition memory as assessed by the novel object recognition task. Moreover, central administration of a single acute dose of HFI-419 also improved spatial working memory, as determined by increased spontaneous alternation in the plus maze. IRAP inhibitors are therefore able to enhance different forms of memory that involve distinct brain circuitries (47, 48) .
The demonstration that HFI-419 enhances glucose uptake in the hippocampal slices provides a potentially important mechanism of action and is supported by previous observations of an identical effect elicited by the peptide inhibitors of IRAP (21) . Our working hypothesis is that in neurons where IRAP and GLUT4 are colocalized, the IRAP inhibitors extend the half-life of IRAP and GLUT4 at the plasma membrane by altering the trafficking of these two proteins. The increased levels of IRAP and GLUT4 on the cell surface result in more glucose being taken up by the neurons (21) . Exogenous glucose administration has been shown to facilitate memory in rodents (49, 50) and to reverse memory deficits in animals (51, 52) and in humans (22, 50) .
Novelty and effectiveness of screening strategy
In addition to hit identification through virtual screening, the computational iterative drug refinement strategy adopted in this study provided a valuable and cost-effective approach to support lead optimization efforts (32) . From a single compound identified in the first round of screening, 2 distinct classes of small molecular weight IRAP inhibitors emerged, following consecutive rounds of either 3D shape-based or core structure-based sequential screens, with successful "hit" rates of between 6 -10%. Minor conservative modification of a functional group of the highest affinity compound identified by virtual screening resulted in a 5-fold improvement in affinity and demonstrated efficacy in biological assays, including 2 in vivo tests of memory function.
The previous reported success of the utility of homology models in virtual screening was predominantly in in silico ligand design, where the models were employed to identify novel compounds based on the structure of known ligands (32, 53) . However, in the less common cases where the homology models were used for high throughput in silico screening for compounds for new targets, the majority of the models were based on crystal structures of proteins with high sequence homology with the targets. This often resulted in the identification of compounds that also interacted with high affinity with the protein on which the model was based (32, 53) . In contrast, IRAP and LTA4H share only 41% sequence identity across the catalytic domain, including distinct differences enabling the identification of inhibitors of IRAP that did not bind to LTA4H.
CONCLUSIONS
Our successful development of a potent, selective, and centrally active class of IRAP inhibitors validates the enzyme as a promising target for therapeutic strategies directed toward cognitive disorders. The small-molecule inhibitors of IRAP identified in this study will also provide valuable pharmacological tools for delineating the physiological roles of the enzyme. This body of work also highlights the value of computational drug discovery, not only in accelerating the identification of hit compounds but also in their development into lead series. 
